Vectura Group plc today announces its preliminary results for the year ended 31 December 2019. For full details, please click here.
Commenting on the results, Will Downie, Chief Executive Officer of Vectura, said: “I am pleased to report a solid set of results for 2019 which were ahead of expectations, underpinned by continued flutiform® revenue growth. We have begun to execute on our new strategy to become an industry-leading specialist inhalation services company, as well as adding two very experienced CDMO executives to our leadership team and driving extensive activities to diversify our customer base.
“We enter 2020 with a strong, cash generative business with several near-term catalysts expected, including VR315 (US) and QVM149 approvals, and the framework in place to deliver on our service focused business strategy, which fits well within an attractive inhaled market opportunity.”
Will Downie, Chief Executive Officer, and Paul Fry, Chief Financial Officer, will present the Preliminary Results for analysts at 9.30am GMT today, 17 March 2020. To join via webcast, please click here. Alternatively, use the dial-in details below.
Participant code: 6690667
Participant local dial-in: +44 (0) 207 1928000
Participant free phone dial-in: 0800 376 7922